R&D

Your nose may know more when it comes to COVID-19

A University of Cincinnati ear, nose and throat specialist says your nose may hold a clue in identifying COVID-19. The loss of smell may be a key indicator.

Physicians are increasingly recognizing the importance of the nasal cavity in determining the physiology of COVID-19, explains Ahmad Sedaghat, an associate professor in the University of Cincinnati College of Medicine's Department of Otolaryngology-Head and Neck Surgery and an UC Health physician specializing in diseases of the nose and sinuses.

Fast tracks testing of COVID-19 therapies

A novel clinical trial developed by researchers at the University of Pittsburgh School of Medicine launched at UPMC to address one of the most important debates during the COVID-19 pandemic: How should doctors decide between quickly adopting new therapies, such as the anti-malarial drug hydroxychloroquine, and waiting until they are tested in longer clinical trials?

COVID-19 drug lead treatments identified

An international team of researchers has tested more than 10,000 compounds to identify six drug candidates that may help treat COVID-19.

The research, involving University of Queensland scientist Professor Luke Guddat, tested the efficacy of approved drugs, drug candidates in clinical trials and other compounds.

Lancaster academic sees positives in first published clinical trial of COVID-19 treatment

A Lancaster University statistician who worked on the first published large randomised clinical trial for a potential treatment for the COVID-19 virus said the scientific community was coming together to combat the coronavirus. There are currently no specific treatments for COVID-19. However, it is possible that some existing drugs, usually used for other conditions, may have some benefits.

Possible coronavirus drug identified by Australian scientists

A collaborative study led by Monash University's Biomedicine Discovery Institute (BDI) in Melbourne, Australia, with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), has shown that an anti-parasitic drug already available around the world kills the virus within 48 hours.

New guidelines on caring for ICU patients with COVID-19

An international team including McMaster University researchers has come together to issue guidelines for health-care workers treating intensive care unit (ICU) patients with COVID-19. The Surviving Sepsis Campaign COVID-19 panel has released 54 recommendations on such topics as infection control, laboratory diagnosis and specimens, the dynamics of blood flow support, ventilation support, and COVID-19 therapy.

Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)

Nafamostat mesylate (brand name: Fusan), which is the drug used to treat acute pancreatitis, may effectively block the requisite viral entry process the new coronavirus (SARS-CoV-2) uses to spread and cause disease (COVID-19). The University of Tokyo announced these new findings on March 18, 2020.

Research & Development

Your nose may know more when it comes to COVID-19

Fast tracks testing of COVID-19 therapies

COVID-19 drug lead treatments identified

Lancaster academic sees positives in first published clinical trial of COVID-19 treatment

Possible coronavirus drug identified by Australian scientists

New guidelines on caring for ICU patients with COVID-19

Nafamostat is expected to prevent the transmission of new coronavirus infection (COVID-19)

More Pharma News ...